BACKGROUND
Many people with Parkinson disease do not have access to exercise programs that are specifically tailored to their needs and capabilities. This mobile application (app) allows people with Parkinson disease (PD) to access PD-specific exercises that are individually tailored using in-app demographic questions and performance tests which are fed into an algorithm which in turn produces a video-guided exercise program.
OBJECTIVE
To test the feasibility, safety, and signal of efficacy of a mobile app that facilitates exercise for people with PD.
METHODS
A prospective, single cohort design of people with PD who had downloaded the 9zest app for exercise was used for this 12 week pilot study. Participants were encouraged to exercise with the app for ≥150 minutes each week. The primary endpoints were feasibility (app usage and usability questions) and safety (adverse events and falls). The primary endpoints for signal of efficacy were a comparison of the in-app baseline and 8 week outcomes on the 30 second Sit-To-Stand (STS), Timed Up and Go (TUG), and the Parkinson’s Disease Questionnaire 8 (PDQ8).
RESULTS
For feasibility, of the 28 participants that completed the study, 12 participants averaged >150 minutes of app usage per week (3 averaged 120-150, 4 averaged 90-120, and 9 averaged less than 90 minutes). A majority of participants (>73.7%) felt the exercise was of value, provided adequate instruction, and was appropriate for level of function. For safety, there were no serious adverse events that occurred during the app-guided exercise. There were 4 reports of strain/sprain injuries while using the app among 3 participants, none of which necessitated medical attention. For single of efficacy, there was improvement for each of the primary endpoints: STS (P=.008), TUG (P<.001), and PDQ8 (P=.008).
CONCLUSIONS
Independent, video-guided exercise using a mobile app designed for exercise in PD was safe and feasible though there was variability in app usage. Despite this, the results provide evidence for a signal of efficacy as there were improvements in 3 of the 3 outcomes.
CLINICALTRIAL
Fox Trial Finder ID: 005206; Clinicaltrials.gov Identifier: NCT03459586